X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Boehringer Ingelheim Animal Health launches two new swine vaccines in Europe

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Research & Development

New vaccines Ingelvac PRRSFLEX® EU for piglets and ReproCyc® PRRS EU for sows offer sustainable control of Porcine Reproductive and Respiratory Syndrome (PRRS).

Boehringer Ingelheim Animal Health launches two new swine vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS). Ingelvac PRRSFLEX® EU for piglets and ReproCyc® PRRS EU for breeding gilts and sows will be launched in most European countries in October 2015.

PRRS infects pigs around the globe causing reproductive failure in breeding stock and respiratory tract illness, slower growth and increased mortality in growing pigs. As a result, pigs suffer and die which causes economic damage to swine farmers worldwide. With Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU, they now have the opportunity to protect their whole herds against the negative impacts of PRRS.

“We are very confident that the simultaneous launch of our two new vaccines will significantly benefit swine farmers all over Europe”, states Dr Joachim Hasenmaier, responsible for the Corporate Board Divisions Animal Health and Consumer Healthcare at Boehringer Ingelheim. “We have worked hard on developing an effective solution for sustainable whole herd PRRS control, and we are convinced that Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU are the perfect combination.”

Ingelvac PRRSFLEX® EU reduces respiratory clinical signs and is the only piglet-specific PRRS vaccine on the European market. It can be used for the active immunization of healthy pigs from 17 days of age.

With ReproCyc® PRRS EU, breeding gilts and sows affected with the PRRS disease can be safely vaccinated in all stages of the reproductive cycle. This results in a reduction of PRRS-induced reproductive disorders such as an increased number of weak-born piglets or neonatal mortality. Vaccinated gilts and sows show a decreased transplacental virus transmission from infected females to piglets, one main reason why diseases can be perpetuated.

It is estimated that in 2014 approximately 70% of sows and piglets in Europe were PRRS positive.1 PRRS is associated with substantial costs for swine farmers all over the world, largely due to productivity losses as a result of poor reproductive performance and increased mortality, but also due to secondary infections and complications increasing the medication cost.

Previous Post

US FDA grants breakthrough therapy designation for Roche’s investigational medicine ACE910 for people with haemophilia A with factor VIII inhibitors

Next Post

ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Report Indicates UK £62bn Behind In Global R&D Investment
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In